Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has provided an announcement.
BioDlink International Company Limited has released selected unaudited consolidated financial figures for the year ended 31 December 2025 ahead of its formal results, driven by disclosure obligations of its Taiwan-listed major shareholder Center Laboratories. The early release aims to ensure simultaneous access to information for investors in Hong Kong and Taiwan, while noting that the full audited 2025 results are expected later in March 2026.
The company disclosed that its total net assets fell to RMB625.8 million at end-2025 from RMB729.7 million a year earlier, reflecting lower current and non-current assets alongside reduced liabilities. Management stressed that the 2025 figures are unaudited, constitute a profit forecast under takeover rules, and do not meet the usual reporting standards due to a granted waiver, prompting cautions to shareholders and investors when assessing an ongoing takeover offer and trading the shares.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
BioDlink International Company Limited is a Hong Kong-incorporated company listed on the Stock Exchange of Hong Kong. Through its subsidiaries, it operates in the biopharmaceutical sector and is backed by substantial shareholder Center Laboratories, Inc., whose own listing in Taiwan subjects BioDlink to additional cross-border disclosure requirements.
Average Trading Volume: 3,619,731
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.13B
For detailed information about 1875 stock, go to TipRanks’ Stock Analysis page.